13F Holdings
中文EN

HYFT MindWalk Holdings Corp. IFRS

Pharmaceutical Preparations · Nasdaq · SEC CIK 1715925 · Reporting currency CAD · Fiscal year ends 04/30

Financial factors as of 2026-01-31 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY28.5%
TTM net income YoY73.2%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin60.3%
Operating margin—
Net margin-66.5%
FCF margin-64.8%
EBITDA margin—

Returns

ROE-61.5%
ROA-35.7%
ROIC (approx.)—
Asset turnover0.54x

Leverage & solvency

Liabilities / assets35.4%
Debt / equity0.00x
Current ratio3.74x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.91x
Accruals ratio-3.1%
Payout ratio—
Capex / revenue4.0%

Factor history charts and full statement history on Pro 🔒

Financial statements

Unit: CAD FY2025*2025-04-30FY2024*2024-04-30FY2023*2023-04-30FY2022*2022-04-30FY2021*2021-04-30
Income statement
Revenue24.52M24.52M20.66M19.36M17.91M
Cost of revenue10.97M12.46M9.10M8.38M6.37M
Gross profit13.55M12.05M11.56M10.98M11.54M
R&D expense4.94M4.04M14.10M7.66M1.97M
SG&A expense14.73M15.59M15.38M15.38M1.44M
Interest expense199,000402,000746,000979,000804,000
Pretax income-34.27M-28.70M-27.75M-15.85M-6.00M
Income tax-4.03M-2.59M-1.19M861,0001.34M
Net income-30.23M-26.11M-26.56M-16.71M-7.34M
EPS (basic)-0.91-1.02-1.07-0.85-0.45
EPS (diluted)-0.91-1.02-1.07-0.85-0.45
Balance sheet
Cash & equivalents10.79M3.54M8.37M30.05M41.84M
Inventory2.10M2.14M2.06M1.61M1.20M
Current assets18.75M11.49M16.79M37.47M48.86M
PP&E, netmay include right-of-use assets (IFRS)15.76M16.70M10.39M10.39M4.02M
Goodwill8.23M7.69M19.17M19.64M7.78M
Intangibles1.07M23.56M30.93M32.39M6.06M
Total assets44.44M59.99M77.81M93.65M66.96M
Current liabilities9.01M8.12M5.92M9.29M6.07M
Total liabilities20.82M24.31M20.01M18.36M10.04M
Shareholders' equity23.63M35.68M58.51M75.28M56.92M
Shares outstanding46.15M26.94M25.05M24.48M19.17M
Cash flow statement
Operating cash flow-6.41M-3.18M-19.83M-9.92M-600,000
Capital expenditure799,0001.40M1.50M1.07M1.38M
Free cash flow-7.21M-4.58M-21.33M-10.99M-1.98M
Investing cash flow-799,000-1.56M-1.97M-5.21M-2.46M
Financing cash flow14.89M1.02M-621,0002.88M43.38M
Depreciation & amortization5.12M5.74M6.68M3.77M2.74M
Stock-based compensation445,0001.53M1.94M3.08M2.75M

Free plan shows the latest 5 periods; Pro shows all 6 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· Amounts are in the company's reporting currency, CAD, not USD; the site does no currency conversion.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.